NEWSROOM

Medical Devices

BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference

BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference

Feb 20, 2026

POMPANO BEACH, Fla., February 20, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today announced that Company management will present at the 46th Annual TD Cowen Healthcare Conference being held in Boston, MA. 46th Annual TD Cowen Healthcare Conference: Format: Presentation...

Aclarion Publishes 2026 Shareholder Letter from the Chairman

Aclarion Publishes 2026 Shareholder Letter from the Chairman

Feb 5, 2026

Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028 ATM terminated in early 2025 and ELOC expired December 31, 2025 Broomfield, CO, February 5, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians...

BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference

BioStem Technologies Highlights Alignment with FDA’s Openness to Bayesian Statistical Approaches in Clinical Research

Feb 3, 2026

POMPANO BEACH, Fla., February 3, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent remarks from U.S. Food and Drug Administration (FDA) leadership signaling openness to expanded use of Bayesian statistical methodologies in clinical...

BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference

BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings’ Surgical and Wound Care Business

Jan 21, 2026

Accelerates expansion of BioStem’s commercial organization through integration of an experienced national sales force Expands access to major GPO networks, strengthening BioStem’s position across hospital settings Barry Hassett promoted to Chief Commercial Officer Conference call scheduled for tomorrow, January 22nd at 8am ET POMPANO BEACH, FL, January 21, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech...

Cardiac Biotech Solutions Activates China Production Pipeline for MyCardia AT and Moves into Final NMPA Submission Phase

Cardiac Biotech Solutions Activates China Production Pipeline for MyCardia AT and Moves into Final NMPA Submission Phase

Jan 15, 2026

Regulated manufacturing, hospital field trials, and regulatory filings now underway with Ebulent Medical in Shenzhen LAS VEGAS, NV, January 15, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Cardiac Biotech Solutions, Inc. (OTCID: CBSC) (“CBSC” or the “Company”), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products, today provided an update on the execution of its China market entry plan for its MyCardia AT cardiac event...

SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025

SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025

Jan 13, 2026

Anticipated strong revenue growth driven by higher unit sales of SSi Mantra surgical robotic system Fort Lauderdale, FL, January 13, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced preliminary unaudited revenue and other...

Aclarion Publishes 2026 Shareholder Letter from the Chairman

Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028

Jan 13, 2026

Debt-Free Balance Sheet With $21.6 Million in Cash BROOMFIELD, Colo., Jan. 13, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of a $10.4 million...

SS Innovations Appoints Milan Rao as Global Chief Operating Officer and Chief Financial Officer

SS Innovations Appoints Milan Rao as Global Chief Operating Officer and Chief Financial Officer

Jan 8, 2026

SS Innovations International, Inc. appoints seasoned executive Milan Rao to drive global growth, operational scale, and expanded access to affordable robotic surgery. Fort Lauderdale, FL, January 8, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global...

Aclarion Publishes 2026 Shareholder Letter from the Chairman

Aclarion Provides 2025 Update and 2026 Corporate Outlook

Jan 8, 2026

Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025 Annual Nociscan scan volumes increased 69% year-over-year in 2025 Debt-free balance sheet with $12.0 million in cash as of December 31, 2025, extending cash runway into 2027 and providing strategic flexibility for continued commercial growth Company aims to enroll approximately 25% of patients in CLARITY trial by the end of Q2 2026, with the first internal readout on interim data anticipated in Q3 2026 BROOMFIELD, Colo.,...

SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025

SS Innovations Develops New Instruments to Advance Robotic Surgery in Large, Underserved Patient Segments, including Pediatric and Cardiac Markets

Jan 6, 2026

Smaller 5-millimeter instruments to be incorporated into the SSi Mantra surgical robotic system Takeways: SS Innovations International enhances the SSi Mantra platform with new 5mm robotic instruments for high-precision, small-anatomy surgeries SS Innovations International leverages SSi Mantra to expand access to pediatric and cardiac robotic surgery in underserved global markets Ongoing innovation by SS Innovations International positions SSi Mantra as a cost-effective, scalable solution for...

Aclarion Publishes 2026 Shareholder Letter from the Chairman

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

Jan 6, 2026

Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational requirements to screen and enroll patients in CLARITY First readout on interim data expected after initial cohort of patients achieves 3-month follow up visit in 3Q 2026 BROOMFIELD, Colo., Jan. 06, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion,...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

Dec 18, 2025

Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority of BioStem’s non-acute revenue, treatment for pressure ulcers, also remains unaffected by CMS LCD updates POMPANO BEACH, FL, December 18, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and...

SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025

SS Innovations Submits 510(k) Premarket Notification to the FDA for the Company’s SSi Mantra Surgical Robotic System

Dec 8, 2025

-- Submission covers multiple indications including general, urological, colorectal, gynecological and cardiac surgeries -- SS Innovations has officially submitted a 510(k) application to the U.S. FDA for its SSi Mantra surgical robotic system, aiming for clearance to enter the U.S. market. The SSi Mantra system supports multiple surgical specialties, including general, urological, colorectal, gynecological, and cardiac procedures. The company is simultaneously pursuing EU CE Mark approval to...

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Dec 2, 2025

Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companies Strong track record of launching breakthrough technologies across spine, neurosurgery and pain management Strengthens Aclarion’s commercial execution as the Company expands adoption and payer engagement across the Eastern U.S BROOMFIELD, Colo., December 2, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc.,...

Junction Brain Health Opens Toledo Clinic

Junction Brain Health Opens Toledo Clinic

Dec 1, 2025

Junction Brain Health has opened a new clinic in Toledo, expanding access to advanced, non-invasive treatments for depression across Northwest Ohio and Southeast Michigan. The clinic offers FDA-approved TMS and Spravato® (esketamine) therapies for individuals with treatment-resistant depression, providing coordinated, science-driven brain health care. Staffed by experienced psychiatric providers and TMS technicians, the center delivers individualized care and is now accepting both provider and...

BioStem Technologies Expands Product Access in Medicaid

BioStem Technologies Expands Product Access in Medicaid

Nov 25, 2025

Florida Medicaid Adds BioStem’s VENDAJEⓇ and VENDAJE ACⓇ to Covered Skin Substitutes List Key Takeaways Major reimbursement milestone — Florida Medicaid now covers VENDAJE® and VENDAJE AC®, expanding BioStem’s reach to 13 Medicaid programs nationwide. Significant market expansion — Florida, one of the largest Medicaid states, meaningfully grows BioStem’s addressable patient population and validates its clinical and economic value. Growth catalyst for 2026 — Expanded coverage strengthens...

BioStem Technologies Expands Product Access in Medicaid

BioStem Technologies Reports Third Quarter 2025 Financial Results

Nov 13, 2025

Key Takeaways Consistent Profitability — Q3 2025 net revenue reached $10.5M with $0.8M net income, marking BioStem’s seventh consecutive quarter of positive adjusted EBITDA. Clinical & Regulatory Progress — Positive BioREtain® trial results published in the International Journal of Tissue Repair; FDA reinspection completed with no observations. Strategic Expansion & Partnerships — BioStem secured land for its new Boca Raton HQ, partnered with a Service-Disabled Veteran-Owned Small...

BioStem Technologies Expands Product Access in Medicaid

BioStem Technologies Announces Filing of Restated Financial Statements

Nov 13, 2025

Key Takeaways Restated Financials Filed — BioStem filed restated interim and annual financial statements for 2023–2025, aligning with US GAAP for revenue recognition. Revenue Classification Update — Bona fide services fees from Venture Medical are now treated as contra revenue, lowering gross sales but not impacting EBITDA or cash flow. Audit and Uplist Progress — BioStem’s KPMG-led independent audit will conclude by Q1 2026, supporting plans to uplist and strengthen investor transparency....

American Shared Hospital Services Reports Third Quarter 2025 Financial Results

American Shared Hospital Services Reports Third Quarter 2025 Financial Results

Nov 13, 2025

Third Quarter Revenue Increased 2.5% Period over Period with 42.3% EBITDA Growth Revenue for the First Nine Months Increased 5.6% Year Over Year Signs Existing Health System to 10 Year Extension and an Upgrade to their Gamma Knife System Conference Call Scheduled for 1:00 PM ET Today SAN FRANCISCO, CA, November 13, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of...

SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025

SS Innovations Announces Successful Completion of First Telesurgery Performed with the Company’s SSi Mantra Tele Surgeon Console

Nov 6, 2025

Compact New Console Facilitates Performance of Telesurgeries from a Wide Range of Locations, including Physicians’ Offices Key Takeaways Historic First for Robotic TelesurgerySS Innovations (Nasdaq: SSII) successfully completed the first telesurgery using its SSi Mantra Tele Surgeon Console (TSC), enabling remote operations from any connected location. Compact, Office-Ready DesignThe TSC is a self-contained, chair-based console with 3D visualization and magnetic sensor controls, allowing...

American Shared Hospital Services Reports Third Quarter 2025 Financial Results

American Shared Hospital Services Announces Third Quarter Financial Results Conference Call

Nov 6, 2025

Call Scheduled for November 13th at 1:00 PM ET SAN FRANCISCO, November 6, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its equipment leasing and direct patient care services segments, today announced that the Company will hold a conference call to discuss its third...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Nov 5, 2025

Marks Aclarion’s first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgery Experiencing strong commercial traction in UK as first market worldwide with private insurers covering Nociscan Nociscan reimbursed by three of top four private insurers in UK, giving access to more than 5.2 million covered lives Broomfield, CO, November 5, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) -...

Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University

Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University

Nov 3, 2025

Key Takeaways Q4 government submission in progress — Halberd Corporation, with Mississippi State University, is preparing a U.S. government funding submission to advance post-head-trauma TBI treatment. Phase-2 animal research focus — The sought contract would finance studies measuring biochemical and behavioral efficacy of a multi-part nasal spray across blast and impact TBI models. AI-enhanced assessment & military use case — NeuroSense AI will support multi-modal behavioral analysis;...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025

Oct 30, 2025

Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., October 30, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announces it will release its third quarter 2025 financial results on Thursday, November 13, 2025, and will host a conference call and webcast...

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Oct 22, 2025

Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion’s breakthrough Nociscan solution for chronic low back pain BROOMFIELD, Colo., October 22, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to...

SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025

SS Innovations to Participate in Upcoming Investor Conferences

Oct 21, 2025

Fort Lauderdale, FL, October 21, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer, and Dr. Vishwa Srivastava, Chief Executive Officer – Asia...

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst

Oct 14, 2025

Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted), providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89% year-over-year with third consecutive quarter of record utilization across U.S., U.K., and E.U. markets CLARITY pivotal trial progressing on schedule and early 3-month readouts expected Q2 2026 as AI-driven disc pain biomarker validation continues Webcast scheduled for October 20th at 12:00 pm PT at...

Sono-Tek Wins $2.8 Million Order for Advanced Medical Device Coating Systems

Sono-Tek Wins $2.8 Million Order for Advanced Medical Device Coating Systems

Oct 13, 2025

MILTON, N.Y., October 13, 2025 - - PRISM MediaWire (Press Release Service - Press Release Distribution) - Sono-Tek Corporation (Nasdaq: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced that it has received a purchase order valued at over $2.8 million from a major U.S.-based medical device manufacturer. This order, placed by an existing customer which is ramping up production, includes multiple advanced ExactaCoat MD (Medical Device) systems. The...

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference

Oct 13, 2025

Panel discussion featured at the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London, titled United to Conquer Pain Session Co-Moderator Doug Beall, M.D., underscored that disc chemistry is the critical biomarker for diagnosing the leading cause of chronic low back pain Nociscan® combines MR Spectroscopy and proprietary AI algorithms to deliver data-driven insights that inform treatment decisions to improve patient outcomes BROOMFIELD, Colo., October 13, 2025 - PRISM...

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Oct 7, 2025

Company recognized for breakthrough Nociscan solution for chronic low back pain, one of the most widespread health challenges BROOMFIELD, Colo., October 7, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today...